Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVX Abivax	$70.13 +0.2%	$23.93	$4.77 ▼ $75.51	$4.44B	0.56	3.24 million shs	667,272 shs
GMAB Genmab A/S	$21.43 -5.6%	$21.74	$17.24 ▼ $27.94	$14.56B	0.95	1.08 million shs	1.75 million shs
RDY Dr. Reddy's Laboratories	$13.82 +1.6%	$14.85	$12.26 ▼ $16.89	$11.35B	0.29	1.53 million shs	1.11 million shs
TEVA Teva Pharmaceutical Industries	$16.34 +0.3%	$16.72	$12.47 ▼ $22.80	$18.68B	0.62	13.04 million shs	9.53 million shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVX Abivax	+0.16%	-2.52%	+743.92%	+945.16%	+522.82%
GMAB Genmab A/S	-5.55%	-1.61%	-0.70%	+10.52%	-19.01%
RDY Dr. Reddy's Laboratories	+1.47%	-0.97%	-6.34%	+2.94%	-16.48%
TEVA Teva Pharmaceutical Industries	+0.15%	+6.24%	-2.27%	-3.54%	-2.68%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABVX Abivax	3.476 of 5 stars	4.6	4.0	0.0	2.2	0.8	0.6
GMAB Genmab A/S	3.6719 of 5 stars	3.3	3.0	0.0	3.7	0.0	3.1
RDY Dr. Reddy's Laboratories	2.3432 of 5 stars	2.5	2.0	1.7	2.7	0.0	1.9
TEVA Teva Pharmaceutical Industries	2.9388 of 5 stars	3.6	2.0	0.0	2.6	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABVX Abivax	3.13	Buy	$92.33	31.66% Upside
GMAB Genmab A/S	2.64	Moderate Buy	$37.80	76.39% Upside
RDY Dr. Reddy's Laboratories	3.00	Buy	$16.95	22.69% Upside
TEVA Teva Pharmaceutical Industries	3.25	Buy	$24.71	51.25% Upside

Current Analyst Ratings Breakdown

Latest ABVX, TEVA, GMAB, and RDY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/29/2025	ABVX Abivax	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$70.00 ➝ $112.00
7/23/2025	ABVX Abivax	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$74.00
7/23/2025	ABVX Abivax	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$45.00 ➝ $101.00
7/23/2025	ABVX Abivax	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$42.00 ➝ $70.00
7/23/2025	ABVX Abivax	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$50.00 ➝ $101.00
7/23/2025	ABVX Abivax	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$71.00
7/23/2025	ABVX Abivax	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$33.00 ➝ $95.00
7/18/2025	ABVX Abivax	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$33.00
7/18/2025	ABVX Abivax	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform
7/8/2025	GMAB Genmab A/S	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$45.00 ➝ $46.00
6/26/2025	TEVA Teva Pharmaceutical Industries	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$24.00 ➝ $23.00

(Data available from 8/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABVX Abivax	N/A	N/A	N/A	N/A	$0.69 per share	N/A
GMAB Genmab A/S	$3.12B	4.40	$1.43 per share	14.96	$8.04 per share	2.67
RDY Dr. Reddy's Laboratories	$3.81B	3.03	$1.05 per share	13.17	$4.94 per share	2.80
TEVA Teva Pharmaceutical Industries	$16.54B	1.13	$3.38 per share	4.84	$5.96 per share	2.74

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABVX Abivax	-$190.71M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/11/2025 (Estimated)
GMAB Genmab A/S	$1.14B	$1.76	10.77	12.04	6.89	37.53%	21.23%	17.06%	N/A
RDY Dr. Reddy's Laboratories	$663M	$0.66	20.93	16.85	5.44	16.99%	17.25%	11.63%	N/A
TEVA Teva Pharmaceutical Industries	-$1.64B	-$0.16	N/A	6.21	0.96	-0.95%	46.10%	7.18%	N/A

Latest ABVX, TEVA, GMAB, and RDY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	ABVX Abivax	-$0.9220	N/A	N/A	N/A	$1.19 million	N/A
8/7/2025	Q2 2025	GMAB Genmab A/S	$0.39	$0.54	+$0.15	$0.54	$5.77 billion	$925.00 million
7/30/2025	Q2 2025	TEVA Teva Pharmaceutical Industries	$0.64	$0.66	+$0.02	$0.24	$4.34 billion	$4.18 billion
7/23/2025	Q1 25/26	RDY Dr. Reddy's Laboratories	$0.18	$0.20	+$0.02	$0.20	$88.27 billion	$988.82 million
5/9/2025	Q4 24/25	RDY Dr. Reddy's Laboratories	$0.20	$0.22	+$0.02	$0.22	$83.70 billion	$996.17 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABVX Abivax	N/A	N/A	N/A	N/A	N/A
GMAB Genmab A/S	N/A	N/A	N/A	N/A	N/A
RDY Dr. Reddy's Laboratories	$0.07	0.51%	N/A	10.61%	N/A
TEVA Teva Pharmaceutical Industries	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABVX Abivax	1.29	1.25	1.25
GMAB Genmab A/S	N/A	5.34	5.32
RDY Dr. Reddy's Laboratories	0.01	1.89	1.36
TEVA Teva Pharmaceutical Industries	2.45	1.06	0.77

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABVX Abivax	47.91%
GMAB Genmab A/S	7.07%
RDY Dr. Reddy's Laboratories	3.85%
TEVA Teva Pharmaceutical Industries	54.05%

Insider Ownership

Company	Insider Ownership
ABVX Abivax	N/A
GMAB Genmab A/S	1.54%
RDY Dr. Reddy's Laboratories	2.00%
TEVA Teva Pharmaceutical Industries	0.49%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABVX Abivax	61	63.47 million	N/A	Not Optionable
GMAB Genmab A/S	2,682	641.54 million	631.66 million	Optionable
RDY Dr. Reddy's Laboratories	27,811	834.90 million	818.20 million	Optionable
TEVA Teva Pharmaceutical Industries	36,830	1.15 billion	1.14 billion	Optionable

ABVX, TEVA, GMAB, and RDY Headlines

Recent News About These Companies

iA Global Asset Management Inc. Reduces Stock Position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

August 7 at 6:20 AM | marketbeat.com

Teva’s Ajovy becomes first migraine prevention drug approved for children

August 6 at 4:32 PM | finance.yahoo.com

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Insider Sells $91,763.48 in Stock

August 6 at 4:15 PM | marketbeat.com

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Insider Eric A. Hughes Sells 52,742 Shares

August 6 at 4:15 PM | marketbeat.com

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Insider Sells $91,763.48 in Stock

August 6 at 6:14 AM | insidertrades.com

Natixis Advisors LLC Has $5.12 Million Position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

August 6 at 3:58 AM | marketbeat.com

US FDA approves Teva's Ajovy for migraine prevention in children

August 5, 2025 | reuters.com

TD Asset Management Inc Has $3.62 Million Position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

August 3, 2025 | marketbeat.com

Comparing Teva Pharmaceutical Industries (NYSE:TEVA) and Globeimmune (OTCMKTS:GBIM)

August 2, 2025 | americanbankingnews.com

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Shares Purchased by King Wealth Management Group

August 1, 2025 | marketbeat.com

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Given Average Recommendation of "Buy" by Analysts

August 1, 2025 | americanbankingnews.com

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Given Average Rating of "Buy" by Analysts

August 1, 2025 | marketbeat.com

Teva's Big Pharma Comeback: Why I Think The Market Is Still Missing The Upside

July 31, 2025 | seekingalpha.com

TEVA Q2 Earnings Beat, Revenues Miss on Lower Generics Sales

July 31, 2025 | zacks.com

Teva Pharmaceutical Industries (NYSE:TEVA) Releases FY 2025 Earnings Guidance

July 31, 2025 | marketbeat.com

Zurcher Kantonalbank Zurich Cantonalbank Buys 36,843 Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

July 31, 2025 | marketbeat.com

Teva Pharm's second-quarter profit boosted by branded drugs, US tariff questions remain

July 30, 2025 | msn.com

Teva CEO: Our supply chain puts us in a strong position

July 30, 2025 | youtube.comY

Teva Pharmaceutical Industries Limited (TEVA) Q2 2025 Earnings Call Transcript

July 30, 2025 | seekingalpha.com

Compared to Estimates, Teva Pharmaceutical Industries (TEVA) Q2 Earnings: A Look at Key Metrics

July 30, 2025 | zacks.com

Teva Pharma shares climb 3% after Q2 earnings surpass expectations

July 30, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABVX, TEVA, GMAB, and RDY Company Descriptions

Abivax NASDAQ:ABVX

$70.13 +0.11 (+0.16%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$69.78 -0.35 (-0.50%)

As of 08/8/2025 07:55 PM Eastern

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

Genmab A/S NASDAQ:GMAB

$21.43 -1.26 (-5.55%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$22.42 +0.99 (+4.62%)

As of 08/8/2025 06:49 PM Eastern

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Dr. Reddy's Laboratories NYSE:RDY

$13.82 +0.22 (+1.58%)

Closing price 08/8/2025 03:59 PM Eastern

Extended Trading

$13.80 -0.01 (-0.07%)

As of 08/8/2025 06:40 PM Eastern

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Teva Pharmaceutical Industries NYSE:TEVA

$16.34 +0.05 (+0.31%)

Closing price 08/8/2025 03:59 PM Eastern

Extended Trading

$16.28 -0.06 (-0.37%)

As of 08/8/2025 07:25 PM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time